Mulligan Mobilization vs Shockwave Therapy in Adhesive Capsulitis

December 16, 2025 updated by: Mohamed Ragab Gaber, Cairo University

Mulligan Mobilization Versus Extracorporeal Shockwave Therapy on Ultrasonographic Changes in Patients With Adhesive Capsulitis

To investigate and compare the effects of Mulligan mobilization versus shock wave therapy in patients with adhesive capsulitis on Pain intensity level, Range of motion, Functional disability level, Ultrasonographic changes (soft tissue thickness) and Hand grip strength.

Study Overview

Detailed Description

sixty patients of both genders according to sample size calculation, referred from orthopedist, diagnosed adhesive capsulitis patients. they screened according to inclusion and exclusion criteria. Their age between 40 and 60 years was randomly allocated to three treatment groups.

  • Group A (study group) (n=20) will receive mulligan technique and conventional treatment.
  • Group B (study group) (n=20) will receive extracorporeal shockwave therapy and conventional treatment.
  • Group C (control group) (n=20) will receive conventional treatment only.

Inclusion criteria: patients that will be included in the study will be referred from orthopedic physician with:

  1. Patients referred from orthopedist and diagnosed as frozen shoulder
  2. The age of the participant will be from 40-60 (Agarwal S., et al.2016).
  3. Body mass index from 25- 30 kg/m2.
  4. having a painful stiff shoulder for at least 3 months
  5. having limited ROM of a shoulder joint (ROM losses of 25% or greater compared with the noninvolved shoulder in at least 2 of the following shoulder motions: glenohumeral flexion, abduction and lateral rotation.
  6. ability to complete Disabilities of the Arm, Shoulder and Hand questionnaires (DASH).

Exclusion criteria:

  1. history of surgery on the particular shoulder
  2. Rheumatoid arthritis
  3. painful stiff shoulder after a severe trauma
  4. fracture of the shoulder complex
  5. rotator cuff rupture
  6. tendon calcification.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Giza, Egypt, 12612
        • Faculty of Physical Therapy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Patients referred from orthopedist and diagnosed as frozen shoulder The age of the participant will be from 40-60 (Agarwal S., et al.2016). Body mass index from 25- 30 kg/m2. having a painful stiff shoulder for at least 3 months having limited ROM of a shoulder joint (ROM losses of 25% or greater compared with the noninvolved shoulder in at least 2 of the following shoulder motions: glenohumeral flexion, abduction and lateral rotation.

ability to complete Disabilities of the Arm, Shoulder and Hand questionnaires (DASH).

Exclusion Criteria:

history of surgery on the particular shoulder Rheumatoid arthritis painful stiff shoulder after a severe trauma fracture of the shoulder complex rotator cuff rupture tendon calcification.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: - Group A (study group)
received mulligan technique and conventional treatment
Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier
Other Names:
  • Mobilization with movement
Conventional treatment will be axillary ultrasound and laser ,low loading stretching exercise and home program exercises
Experimental: Group B (study group)
received extracorporeal shockwave therapy and conventional treatment.
Conventional treatment will be axillary ultrasound and laser ,low loading stretching exercise and home program exercises
From sitting with shoulder abducted at 45 degree and elbow flexed and the forearm rested on flat surface, The patients in the intervention group B received shock wave therapy once a week for 4 weeks. The focus probe sets were used and, in each session, patients received ESWT from anterior and posterior directions (on the average 1200 shocks between 0.1 and 0.3 mJ/mm2) up to the maximum threshold of pain tolerance in the shoulder
Experimental: Group C (control group)
received conventional treatment only.
Conventional treatment will be axillary ultrasound and laser ,low loading stretching exercise and home program exercises

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain intensity level.
Time Frame: 4 weeks
measured by Visual analog scale
4 weeks
Range of motion.
Time Frame: 4 weeks
measured by digital goniometer
4 weeks
Functional disability level.
Time Frame: 4 weeks
Determined by Disabilities of the arm, shoulder and hand questionnaire (DASH)
4 weeks
Soft tissue thickness (Capsule thickness)
Time Frame: 4 weeks
measured by musculoskeletal ultrasonography
4 weeks
Hand grip strength
Time Frame: 4 weeks
Measured by hand dynamometer
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mohamed R Gaber, Asst. lect., Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2025

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

February 1, 2026

Study Registration Dates

First Submitted

December 16, 2025

First Submitted That Met QC Criteria

December 16, 2025

First Posted (Actual)

December 30, 2025

Study Record Updates

Last Update Posted (Actual)

December 30, 2025

Last Update Submitted That Met QC Criteria

December 16, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adhesive Capsulitis

Clinical Trials on Mulligan mobilization

Subscribe